Journal «Angiology and Vascular Surgery» • 

2000 • VOLUME 6 • №2

VASAPROSTAN (PROSTAGLANDIN E1) IN THE COMBINED TREATMENT OF PATIENTS WITH AN ISCHEMIC DIABETIC FOOT

A.V. Pokrovsky, V.N. Dan, A.V. Chupin, A.F. Kharazov

The present paper describes the experience gained with the combined treatment of 41 patients with an ischemic diabetic foot and the signs of critical ischemia. Emphasis is laid on the use of prostaglandin E1 (Vasaprostan). The indications and contraindications for the use of the drug are listed. It is demonstrated that patients with an ischemic diabetic foot should undergo the combined treatment. The combined therapy (the conservative Vasaprostan treatment plus vascular reconstruction) resulted in a significant decrease of the percentage of amputations (7.3%). It is stressed that Vasaprostan is highly effective precisely in the combined treatment of patients with an ischemic diabetic foot and the signs of critical ischemia on condition that all treatment procedures are made properly.

KEY WORDS: diabetes mellitus, prostaglandin E1, ischemia.

P. 19-26

« Back

Angiologia.ru - portal for professionals
VLAANT
Lancet
HI-TECHNOLOGY MEDICINE